Selv om det ikke er blevet vist, at phopholipidose udgør en risiko for patienter, der har fået temsirolimus, er det muligt, at kombineret indgift af temsirolimus sammen med andre amphifile stoffer som f. eks. amiodaron eller statiner vil kunne medføre en øget risiko for amphiphil pulmonal toksicitet.
Although phospholipidosis has not been shown to be a risk for patients administered temsirolimus, it is possible that combined administration of temsirolimus with other amphiphilic agents such as amiodarone or statins could result in an increased risk of amphiphilic pulmonary toxicity.